Results 51 to 60 of about 10,125,713 (289)

Monozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms?

Annals of Hepatology, 2016
Multiple genetic and environmental factors interact to determine an individual’s predisposition to non-alcoholic fatty liver disease and its phenotypic characteristics. Association studies have found a number of alleles associated with the development of
Jane I. Grove, Mark Austin, Jeremy Tibble, Guruprasad P. Aithal, Sumita Verma   +4 more
doaj   +1 more source

Effect of quercetin on the clinical course of non-alcoholic steatohepatitis and diabetic kidney disease against comprehensive treatment of type 2 diabetes patients

Mìžnarodnij Endokrinologìčnij Žurnal, 2020
Background. The purpose of the study was to determine the probable effect of a complex of metformin, rosuvastatin, essential phospholipids, and quercetin on the clinical course of non-alcoholic steatohepatitis, diabetic kidney disease, type 2 diabetes ...
O.S. Khukhlina, A.A. Antoniv, Z.Ya. Kotsiubiichuk   +2 more
doaj   +1 more source

Src kinase as a potential therapeutic target in non‐alcoholic and alcoholic steatohepatitis

Clinical and Translational Discovery, 2022
Non‐alcoholic steatohepatitis (NASH) and alcohol‐associated steatohepatitis (ASH) are the major cause of liver‐related mortality with limited therapeutic options available.
Dhadhang Wahyu Kurniawan, Richell Booijink, Arun Kumar Jajoriya, Garima Dhawan, Divya Mishra, Dorenda Oosterhuis, Josepmaria Argemi, Gert Storm, Peter Olinga, Ramon Bataller, Sujit Kumar Mohanty, Durga Prasad Mishra, Jai Prakash, Ruchi Bansal   +13 more
doaj   +1 more source

The therapeutic landscape of non-alcoholic steatohepatitis. [PDF]

, 2016
Non-alcoholic steatohepatitis (NASH) is characterized by lobular inflammation and hepatocellular ballooning, and may be associated with liver fibrosis leading to cirrhosis and its complications.
Perazzo, Hugo, Hugo Perazzo, Dufour, Jean-François, Dufour, J. F., Jean‐François Dufour   +4 more
core   +1 more source

Pathohistological characteristics of steatohepatitis on needle biopsy sample from 100 patients [PDF]

Medicinski Podmladak, 2019
Introduction: Steatohepatitis is a form of fatty liver disease, in which there is a deposit of fat and steatosis which occurs in two forms: alcoholic and non-alcoholic fatty liver disease.
Milićević Anđela, Lazović Nevena, Tomanović Nada   +2 more
doaj  

Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution

, 2022
Hepatology, EarlyView.
Ralf Weiskirchen
wiley   +1 more source

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models

Journal of Cachexia, Sarcopenia and Muscle, 2021
Background Non‐alcoholic fatty liver (NAFL) disease (NAFLD) is the most common chronic liver disease in the world. While most subjects have ‘inert’ NAFL, a subset will progress to non‐alcoholic steatohepatitis (NASH) and its life‐threatening ...
Maxime Nachit, Maxime De Rudder, Jean‐Paul Thissen, Olivier Schakman, Caroline Bouzin, Yves Horsmans, Greetje Vande Velde, Isabelle Anne Leclercq   +7 more
doaj   +1 more source

Aloperin improves liver non-alcoholic steatohepatitis in vitro and in vivo

, 2020
Introduction The aim of this work is to investigate the inhibitory effect of aloperin (Alo) on hepatocyte apoptosis in non-alcoholic fatty liver disease, and the underlying mechanism.
Sumei Lu, Ruyu Liu, Min Yang, Shaofei Wu, Zhongsheng Guo, Liwei Guo, Yong An   +6 more
core   +1 more source

Evaluating the effect of γ‐oryzanol on MASLD pathology using a medaka fish model

FEBS Open Bio, EarlyView.
This study explores a liver disease called MASLD, which is increasing worldwide and can lead to serious damage. Researchers used medaka fish instead of rodents to test a food compound, γ‐oryzanol. Fish fed this compound had less liver fat and healthier gut bacteria.
Yukako Ito, Haduki Asano, Ayano Ueki, Joe Sakamoto, Yasuhiro Kamei, Hayato Tokumoto, Ayaka Yazawa, Shigeki Kamitani   +7 more
wiley   +1 more source

[Non-alcoholic steatohepatitis - from NAFLD to MAFLD]

, 2011
Non-alcoholic steatohepatitis (NASH) as one entity of non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and accompanies the rise in the prevalence of obesity, diabetes mellitus, hypertension and hyperlipidemia ...
Jean-François Dufour, Balmer, Maria Luisa, Maria Luisa Balmer, Dufour, Jean-François   +3 more
core   +1 more source